"This strategic alliance by the two companies aims to broaden access to first-line treatment for patients with cEGFR-mutant non-small cell lung cancer"
[by Lee, Young Sung] Janssen Korea, the Korean pharmaceutical division of Johnson & Johnson (J&J), announced on November 10 that it will collaborate with Yuhan Corporation to co-promote the Rybrevant (amivantamab) + Leclaza (lazertinib) combination 바카라 전략 in South Korea.
This combination 바카라 전략 received approval from the Ministry of Food and Drug Safety (MFDS) in January as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
The two companies signed an agreement on October 31, formalizing their partnership to co-promote the combination 바카라 전략.
Johnson & Johnson, which holds the global rights to the combination 바카라 전략, has been spearheading its global promotion of the combination 바카라 전략. Under this new agreement, J&J will collaborate with Yuhan Corporation to co-promote the combination 바카라 전략 in Korea. Previously, Yuhan Corporation had been responsible for promoting Leclaza mono바카라 전략, and this partnership expands its role to include co-promotion of the combination 바카라 전략.
Johnson & Johnson will remain responsible for the distribution of Rybrevant, while 바카라 전략 Corporation will oversee the distribution of Leclaza.
Rybrevant is the first bispecific antibody designed to simultaneously inhibit EGFR and MET, while Leclaza is a third-generation EGFR tyrosine kinase inhibitor (TKI). The global Phase 3 clinical trial (MARIPOSA) demonstrated the combination’s significant clinical efficacy and favorable safety profile. This joint marketing initiative was established in alignment with both companies’ agreed-upon objectives to actively promote the therapeutic value of the Rybrevant + Leclaza combination therapy among Korean healthcare professionals and to enhance patient access to this treatment.
“Through this strategic partnership with Yuhan Corporation, we hope that more Korean patients with non-small cell lung cancer will be able to benefit from the Rybrevant + Leclaza combination therapy. Johnson & Johnson’s mission is to transform patients’ lives through science and innovation, and we will continue to strive to provide better treatment opportunities through close collaboration and open communication with Yuhan Corporation,” stated Christian Rodseth, Senior Vice President and Managing Director of J&J Innovative Medicine North Asia, South Korea.
On the other hand, in addition to Leclaza mono바카라 전략, which Yuhan Corporation holds the right to and is currently promoting in Korea, Johnson & Johnson will serve as the exclusive promoter of second-line or later treatment for adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. Johnson & Johnson will also remain the exclusive supplier of Rybrevant.